These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
94 related items for PubMed ID: 3344604
41. Mutation screening of the RYR1-cDNA from peripheral B-lymphocytes in 15 Swedish malignant hyperthermia index cases. Broman M, Gehrig A, Islander G, Bodelsson M, Ranklev-Twetman E, Rüffert H, Müller CR. Br J Anaesth; 2009 May; 102(5):642-9. PubMed ID: 19346234 [Abstract] [Full Text] [Related]
43. The differential effect of halothane and 1,2-dichlorohexafluorocyclobutane on in vitro muscle contractures of patients susceptible to malignant hyperthermia. Kindler CH, Girard T, Gong D, Urwyler A. Anesth Analg; 2002 Apr; 94(4):1028-33, table of contents. PubMed ID: 11916818 [Abstract] [Full Text] [Related]
45. Phenotyping malignant hyperthermia susceptibility by measuring halothane-induced changes in myoplasmic calcium concentration in cultured human skeletal muscle cells. Girard T, Treves S, Censier K, Mueller CR, Zorzato F, Urwyler A. Br J Anaesth; 2002 Oct; 89(4):571-9. PubMed ID: 12393358 [Abstract] [Full Text] [Related]
46. Does the A3333G mutation in the CACNL1A3 gene, detected in malignant hyperthermia, also occur in central core disease? Vainzof M, Muniz VP, Tsanaclis AM, Silva HC, Rusticci MS. Genet Test; 2000 Oct; 4(4):383-6. PubMed ID: 11216663 [Abstract] [Full Text] [Related]
51. Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in vitro contracture test. Brandt A, Schleithoff L, Jurkat-Rott K, Klingler W, Baur C, Lehmann-Horn F. Hum Mol Genet; 1999 Oct; 8(11):2055-62. PubMed ID: 10484775 [Abstract] [Full Text] [Related]
52. An analysis of the predictive probability of the in vitro contracture test for determining susceptibility to malignant hyperthermia. Hopkins PM, Ellis FR, Halsall PJ, Stewart AD. Anesth Analg; 1997 Mar; 84(3):648-56. PubMed ID: 9052318 [Abstract] [Full Text] [Related]
53. Identification of heterozygous and homozygous individuals with the novel RYR1 mutation Cys35Arg in a large kindred. Lynch PJ, Krivosic-Horber R, Reyford H, Monnier N, Quane K, Adnet P, Haudecoeur G, Krivosic I, McCarthy T, Lunardi J. Anesthesiology; 1997 Mar; 86(3):620-6. PubMed ID: 9066328 [Abstract] [Full Text] [Related]
54. Investigation of malignant hyperthermia in Denmark and Sweden. Ording H, Ranklev E, Fletcher R. Br J Anaesth; 1984 Nov; 56(11):1183-90. PubMed ID: 6487440 [Abstract] [Full Text] [Related]
55. Malignant hyperthermia associated with exercise-induced rhabdomyolysis or congenital abnormalities and a novel RYR1 mutation in New Zealand and Australian pedigrees. Davis M, Brown R, Dickson A, Horton H, James D, Laing N, Marston R, Norgate M, Perlman D, Pollock N, Stowell K. Br J Anaesth; 2002 Apr; 88(4):508-15. PubMed ID: 12066726 [Abstract] [Full Text] [Related]
56. Mutation analysis of two patients with hypokalemic periodic paralysis and suspected malignant hyperthermia. Marchant CL, Ellis FR, Halsall PJ, Hopkins PM, Robinson RL. Muscle Nerve; 2004 Jul; 30(1):114-7. PubMed ID: 15221887 [Abstract] [Full Text] [Related]
57. A mathematical model to improve on phenotyping for molecular genetic research in malignant hyperthermia. Ginz HF, Rüffert H, Levano S, Li Wan Po A, Benthien J, Urwyler A, Girard T. Pharmacogenet Genomics; 2009 Dec; 19(12):972-8. PubMed ID: 19890226 [Abstract] [Full Text] [Related]